Nasal DNA-MVA SIV vaccination provides more significant protection from progression to AIDS than a similar intramuscular vaccination.
about
Mucosal resident memory CD4 T cells in protection and immunopathologyNonhuman primate models for HIV/AIDS vaccine developmentInduction of intestinal immunity by mucosal vaccines as a means of controlling HIV infectionChallenges in mucosal HIV vaccine development: lessons from non-human primate modelsMucosal B Cells Are Associated with Delayed SIV Acquisition in Vaccinated Female but Not Male Rhesus Macaques Following SIVmac251 Rectal ChallengeVaccine-Elicited Mucosal and Systemic Antibody Responses Are Associated with Reduced Simian Immunodeficiency Viremia in Infant Rhesus MacaquesInduction of Potent and Long-Lived Antibody and Cellular Immune Responses in the Genitorectal Mucosa Could be the Critical Determinant of HIV Vaccine Efficacy.Immunogenicity of viral vector, prime-boost SIV vaccine regimens in infant rhesus macaques: attenuated vesicular stomatitis virus (VSV) and modified vaccinia Ankara (MVA) recombinant SIV vaccines compared to live-attenuated SIV.Use of nonhuman primate models to develop mucosal AIDS vaccines.Humoral immunity induced by mucosal and/or systemic SIV-specific vaccine platforms suggests novel combinatorial approaches for enhancing responses.Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques.Novel mucosal DNA-MVA HIV vaccination in which DNA-IL-12 plus cholera toxin B subunit (CTB) cooperates to enhance cellular systemic and mucosal genital tract immunityImproving the MVA vaccine potential by deleting the viral gene coding for the IL-18 binding protein.Rapid SIV Env-specific mucosal and serum antibody induction augments cellular immunity in protecting immunized, elite-controller macaques against high dose heterologous SIV challenge.Enhanced mucosal immune responses to HIV virus-like particles containing a membrane-anchored adjuvant.Induction of mucosal and systemic antibody and T-cell responses following prime-boost immunization with novel adjuvanted human immunodeficiency virus-1-vaccine formulationsPartial efficacy of a VSV-SIV/MVA-SIV vaccine regimen against oral SIV challenge in infant macaquesPurification and functional characterization of mucosal IgA from vaccinated and SIV-infected rhesus macaquesTechnologies for enhanced efficacy of DNA vaccines.HIV DNA Vaccine: Stepwise Improvements Make a Difference.Immunogenicity of HIV virus-like particles in rhesus macaques by intranasal administration.Expression of interleukin-15 and interleukin-15Rα in monocytes of HIV type 1-infected patients with different courses of disease progression.Persistent Low-Level Replication of SIVΔnef Drives Maturation of Antibody and CD8 T Cell Responses to Induce Protective Immunity against Vaginal SIV InfectionChemokine-adjuvanted electroporated DNA vaccine induces substantial protection from simian immunodeficiency virus vaginal challengeImmunogenicity of a vaccine regimen composed of simian immunodeficiency virus DNA, rMVA, and viral particles administered to female rhesus macaques via four different mucosal routesAn effective vaccination approach augments anti-HIV systemic and vaginal immunity in mice with decreased HIV-1 susceptible α4β7high CD4+ T cells.Comparison of systemic and mucosal vaccination: impact on intravenous and rectal SIV challenge.Virus-Like Particles Displaying Trimeric Simian Immunodeficiency Virus (SIV) Envelope gp160 Enhance the Breadth of DNA/Modified Vaccinia Virus Ankara SIV Vaccine-Induced Antibody Responses in Rhesus Macaques.Antigen-dependent competition shapes the local repertoire of tissue-resident memory CD8+ T cells.Resistance to infection, early and persistent suppression of simian immunodeficiency virus SIVmac251 viremia, and significant reduction of tissue viral burden after mucosal vaccination in female rhesus macaquesRhesus macaque rectal and duodenal tissues exhibit B-cell sub-populations distinct from peripheral blood that continuously secrete antigen-specific IgA in short-term explant cultures.Prime-boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1.Alternate mechanisms of initial pattern recognition drive differential immune responses to related poxviruses.Immunogenicity and efficacy of DNA/MVA HIV vaccines in rhesus macaque models.DNA Vaccine-Induced Long-Lasting Cytotoxic T Cells Targeting Conserved Elements of Human Immunodeficiency Virus Gag Are Boosted Upon DNA or Recombinant Modified Vaccinia Ankara Vaccination
P2860
Q26823137-0E02A4B5-DE4F-4EC8-9113-93BD39A9ED28Q26861148-728C2876-4776-4525-8DEC-B2D798B0B4F9Q27001897-478D2062-6BCC-4FC8-ABDD-7AB6567591A1Q27022152-6DEBF172-A7CC-40A8-9697-E60EC11400C6Q27318151-4F802F5E-9FBA-43F9-A8C6-3E29A8096BC6Q28830298-56F54018-DD2D-473F-8F14-1D2AC374D065Q33611645-E4A44997-401F-4287-B909-60D7D23B5C34Q33653655-AEF8E52A-A276-4355-988A-07A244EC7971Q33666002-CEA06241-EB0C-460D-8C5C-4B2F4810077BQ33915690-18732F4D-8BE6-44FB-9674-7351E2DB14F3Q33966586-D587F5EB-86E9-4B92-B668-9954CFDDFB51Q34172564-55AA4B45-F8B5-4FD3-84D1-85E4F80A2F20Q34182371-51569D4E-D166-478F-9463-CBC12B33DF6AQ34574409-F09FBC8C-D2AF-4DA1-9626-89E255D8B256Q34576055-EBB6FE32-6CFE-461B-B6D8-5C0CFF66A43EQ34641666-5E03A91F-BCAC-4D86-B079-F1BA7680F281Q34809716-48CAE633-D704-4DCE-8B2F-B5941761EDF0Q35732677-6E268C39-90F8-4B2D-AFAB-99B2CBA24FC3Q35802958-562D0AE6-2FBD-4D29-964C-3EC802E3547AQ35826742-4554C6DC-9714-418F-8FE0-F5C418CE6739Q36017750-DF1721E9-6D2E-442E-893C-478306D05C82Q36050117-BDDF230D-3AA7-4225-BFD3-ECF808404CB2Q36222317-3A02BF1D-2F9C-4104-A7D2-0C2698527201Q36258203-72F13756-3DA5-42A8-8BB3-3A80F9B91353Q36760192-61B37A83-4F66-4E15-816F-5C3977924E9BQ37030417-A4ED23D4-98DF-4057-9A87-0CBA94F35AA0Q37067177-A868CD31-56C0-4FDD-B7F3-1908272491FBQ37253001-080EC777-5ED0-4D4B-9561-954AE87C4875Q37500355-A90488CD-352D-4E43-9A5A-237829F22F94Q37547763-067748EB-92D6-40C9-BD01-BF16E1640D66Q37564860-456BCAEE-05AE-40BE-B4D9-897C7F9AF690Q37785949-DD176750-0890-4191-811A-0F22B90727AEQ39667525-2537890B-D912-4184-90CE-40F892EF32F4Q40071705-22E45670-F794-47EB-91C7-1FE06F25BFB5Q58711069-62895B08-D687-4507-B77A-2593519CEDFF
P2860
Nasal DNA-MVA SIV vaccination provides more significant protection from progression to AIDS than a similar intramuscular vaccination.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Nasal DNA-MVA SIV vaccination ...... lar intramuscular vaccination.
@en
Nasal DNA-MVA SIV vaccination ...... lar intramuscular vaccination.
@nl
type
label
Nasal DNA-MVA SIV vaccination ...... lar intramuscular vaccination.
@en
Nasal DNA-MVA SIV vaccination ...... lar intramuscular vaccination.
@nl
prefLabel
Nasal DNA-MVA SIV vaccination ...... lar intramuscular vaccination.
@en
Nasal DNA-MVA SIV vaccination ...... lar intramuscular vaccination.
@nl
P2093
P2860
P356
P1433
P1476
Nasal DNA-MVA SIV vaccination ...... ilar intramuscular vaccination
@en
P2093
A Aldovini
A Carville
D C Montefiori
E Micewicz
K G Mansfield
P A Kozlowski
R L Wilson
P2860
P2888
P304
P356
10.1038/MI.2009.103
P577
2009-09-09T00:00:00Z